TIDMSYNC
RNS Number : 2150H
Syncona Limited
30 July 2019
Syncona Limited
Result of Annual General Meeting
30 July 2019
At the Annual General Meeting of the Company held today, all
Resolutions as set out in the 'Notice of the 2019 Annual General
Meeting' dated 27 June 2019 sent to shareholders of the Company
(the "Notice") were duly passed.
Resolutions 1 to 13 were proposed as ordinary resolutions.
Resolution 14 was proposed as a Special Resolution and Resolution
15 was proposed as an Extraordinary Resolution.
Details of the proxy voting results, which should be read
alongside the Notice, are noted below:
No Resolution For Against Abstain Discretion
Receive and consider
the Annual Audited
Financial Statements
of the Company for
the year ended 31
March 2019, together
with the Reports of
the Directors and
1 Auditors thereon 435,492,895 247,369 0 25,774
------------------------------- ------------ ----------- ---------- -----------
Re-appointment Deloitte
LLP (Guernsey Branch)
2 as Auditors 435,511,635 24,433 214,970 15,000
------------------------------- ------------ ----------- ---------- -----------
Authorise the Directors
to determine the remuneration
3 of the Auditors 435,733,447 4,076 2,742 25,774
------------------------------- ------------ ----------- ---------- -----------
Re-elect Jeremy Tigue
4 as a Director 421,376,075 12,076,117 2,288,072 25,774
------------------------------- ------------ ----------- ---------- -----------
Elect Melanie Gee
5 as a Director 435,735,679 0 4,586 25,774
------------------------------- ------------ ----------- ---------- -----------
Re-elect Thomas Henderson
6 as a Director 435,554,836 183,585 1,844 25,774
------------------------------- ------------ ----------- ---------- -----------
Re-elect Rob Hutchinson
7 as a Director 435,726,044 9,635 4,586 25,774
------------------------------- ------------ ----------- ---------- -----------
Re-elect Nigel Keen
8 as a Director 435,304,724 430,954 4,586 25,774
------------------------------- ------------ ----------- ---------- -----------
Re-elect Nick Moss
9 as a Director 435,734,955 724 4,586 25,774
------------------------------- ------------ ----------- ---------- -----------
Re-elect Gian Piero
10 Reverberi as a Director 435,735,679 0 4,586 25,774
------------------------------- ------------ ----------- ---------- -----------
Re-elect Ellen Strahlman
11 as a Director 435,735,679 0 4,586 25,774
------------------------------- ------------ ----------- ---------- -----------
Approve the directors'
12 remuneration report. 435,688,593 49,828 1,844 25,774
------------------------------- ------------ ----------- ---------- -----------
Authority to allot
13 shares 435,723,353 12,326 4,586 25,774
------------------------------- ------------ ----------- ---------- -----------
Authorise the Company
to purchase its own
14 shares 435,722,250 12,693 2,742 28,354
------------------------------- ------------ ----------- ---------- -----------
Disapply pre-emption
15 rights 435,720,338 1,987 4,586 39,128
------------------------------- ------------ ----------- ---------- -----------
A vote withheld is not a vote in law and has not been counted in
the votes for and against a resolution.
In accordance with the Listing Rule 9.6.2, a copy of all the
resolutions passed other than resolutions concerning ordinary
business have been submitted to the UK Listing Authority via the
National Storage Mechanism and will shortly be available for
inspection at http://www.morningstar.co.uk/uk/NSM.
The full text of the resolutions can be found in the Notice,
which is available on the Company's website at
www.synconaltd.com/investors.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel: +44 (0) 20 3981 7940
FTI Consulting
Brett Pollard / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
Copies of this press release and other corporate information can
be found on the company website at: www.synconaltd.com.
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on
investing in and building global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital,
and are established leaders in the development of gene and cell
therapy. We focus on delivering dramatic efficacy for patients in
areas of high unmet need.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGWGUPAMUPBGUU
(END) Dow Jones Newswires
July 30, 2019 06:56 ET (10:56 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2023 to Apr 2024
